Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3995 (Apararenone) and Warfarin DDI Study
NCT02531568Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apararenone in diabetic nephropathy (DN) and Nonalcoholic steatohepatitis (NASH), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Maximum Plasma Concentration of Warfarin at 8 days and Area Under the Curve of Warfarin at 8 days. Started Jun 2015; status: completed.
02
Drugs
apararenone
03
Conditions
diabetic nephropathy (DN)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02531568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531568.